Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

67053 1513184208HCLSReviewBulgariaDecember2017.pdf
Energy Boardroom

Type your email in the box below to read this content NOW:

Interview

Darren Cunningham – Co-founder & CEO, Inflection Biosciences, Ireland

darren-cunninghamDarren Cunningham tells us the story behind Inflection Biosciences (and its name), the rationale of focusing on small molecule cancer treatments, his thoughts on the Irish biotech start-up scene, and his hopes for the company’s future development.

Can you first provide an introduction to Inflection Biosciences to our international audience?

We are an early-stage Irish biotech company founded to develop innovative, small-molecule targeted treatments for significant unmet needs within the oncology space. Through our partnership with the Spanish National Cancer Research Centre (CNIO), we have a number of molecules in the preclinical stage that we hope to take into clinical trials in the coming years, subject to positive preliminary data and required regulatory approvals.

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: